vimarsana.com

Temporary Use Authorization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ABIONYX Pharma Announces Its Cash Position and Provides an Activity Update for the 3rd Quarter 2021

Regulatory News: ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible) (Paris:ABNX) a next-generation biotech company dedicated to the discovery and development of innovative therapies, announces

France generalArthur rouillLouis victor delouvrierRegulatory newsTemporary use authorizationVictor delouvrier

Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Erik atkissonProgeroid laminopathiesDavid coryCompany annual report on formEiger biopharmaceuticals incCommittee for medicinal products human useProgram updatesEiger biopharmaceuticalsHepatitis delta virusPeginterferon lambdaRare metabolicProcessing deficient progeroidMedicinal productsHuman useTemporary use authorizationErik atkisson general counsel

ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal

Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 ABNX PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced

Arthur rouillLouis victor delouvrierRegulatory newsTemporary use authorizationVictor delouvrier

ABIONYX Pharma Announces Positive Preclinical Results in a Model of Uveitis and Launches the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its bio-HDL

Positive preclinical results in a model of uveitis Development of the first class of biomedicines in ophthalmology with bio-HDL Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852

United statesFrance generalCatherine creuzot garcherLouis victor delouvrierNicolas merigeauChristophe baudouinOphthalmologica internationalisAmerican society of ophthalmologyCentre hospitalier nationalFood science centerHead of the ophthalmology departmentUniversity hospital of dijonEuropean medicines agencyUniversity professorOrphan drugTemporary use authorization

vimarsana © 2020. All Rights Reserved.